Please assess the completion status of the following clinical trial:

Trial Title: Rectal Indomethacin to Prevent Post-ERCP Pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing diagnostic or therapeutic ERCP.~Exclusion Criteria:~* Unwillingness or inability to consent for the study;~* Age \< 18 years old;~* Intrauterine pregnancy;~* Breastfeeding mother;~* Standard contraindications to ERCP;~* Allergy to NSAIDs;~* Received NSAIDs in prior 7 days;~* Renal failure (Cr \>1.4mg/dl=120umol/l);~* Active or recurrent (within 4 weeks) gastrointestinal hemorrhage;~* Acute pancreatitis within 72 hours;~* Known pancreatic head mass;~* Subject with prior biliary sphincterotomy now scheduled for repeat biliary therapy without anticipated pancreatogram;~* ERCP for biliary stent removal or exchange without anticipated pancreatogram;~* Known active cardiovascular or cerebrovascular disease.~* Presence of coagulopathy before the procedure or received anticoagulation therapy within three days before the procedure;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Pre-ERCP group (Type: EXPERIMENTAL): Pre-ERCP rectal Indomethacin in all patients.
- Post-ERCP group (Type: ACTIVE_COMPARATOR): Post-ERCP rectal Indomethacin in high-risk patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).